Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial.

被引：4
|
作者：
Mok, Tony
Cheng, Ying
Zhou, Xiangdong
Lee, Ki Hyeong
Nakagawa, Kazuhiko
Niho, Seiji
Tsuji, Fumito
Rosell, Rafael
Jaime, Jesus Corral
Migliorino, Maria Rita
Pluzanski, Adam
Linke, Rolf Gerhard
Sbar, Eric
Wang, Tao
Wu, Yi-Long
机构：
[1] Chinese Univ Hong Kong, Hong Kong, Peoples R China
[2] Jilin Canc Hosp, Changchun, Jilin, Peoples R China
[3] Third Mil Univ, Affiliated Hosp 1, Chongqing, Peoples R China
[4] Chungbuk Natl Univ Hosp, Chungcheong, South Korea
[5] Kinki Univ, Fac Med, Osakasayama, Japan
[6] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan
[7] SFJ Pharmaceut Grp Inc, Osaka, Japan
[8] Catalan Inst Oncol, Barcelona, Spain
[9] Hosp Virgen Rocio, Seville, Spain
[10] Azienda Osped San Camilo Forlanini, Rome, Italy
[11] Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland
[12] Inst Oncol, Warsaw, Poland
[13] SFJ Pharmaceut Inc, Pleasanton, CA USA
[14] Pfizer Inc, Collegeville, PA USA
[15] Pfizer Inc, Groton, CT 06340 USA
[16] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[17] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 18期
关键词：
D O I：
10.1200/JCO.2017.35.18_suppl.LBA9007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA9007
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial
    Mok, Tony
    Cheng, Ying
    Zhou, Xiangdong
    Lee, Ki Hyeong
    Nakagawa, Kazuhiko
    Niho, Seiji
    Tsuji, Fumito
    Rosell, Rafael
    Jaime, Jesus Corral
    Migliorino, Maria Rita
    Pluzanski, Adam
    Linke, Rolf Gerhard
    Sbar, Eric
    Wang, Tao
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
    Wu, Yi-Long
    Cheng, Ying
    Zhou, Xiangdong
    Lee, Ki Hyeong
    Nakagawa, Kazuhiko
    Niho, Seiji
    Tsuji, Fumito
    Linke, Rolf
    Rosell, Rafael
    Corral, Jesus
    Migliorino, Maria Rita
    Pluzanski, Adam
    Sbar, Eric I.
    Wang, Tao
    White, Jane Liang
    Nadanaciva, Sashi
    Sandin, Rickard
    Mok, Tony S.
    LANCET ONCOLOGY, 2017, 18 (11): : 1454 - 1466
  • [3] Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050)
    Cheng, Ying
    Mok, Tony S.
    Zhou, Xiangdong
    Lu, Shun
    Zhou, Qing
    Zhou, Jianying
    Du, Yingying
    Yu, Ping
    Liu, Xiaoqing
    Hu, Chengping
    Lu, You
    Zhang, Yiping
    Lee, Ki Hyeong
    Nakagawa, Kazuhiko
    Linke, Rolf
    Wong, Chew Hooi
    Tang, Yiyun
    Zhu, Fanfan
    Wilner, Keith D.
    Wu, Yi-Long
    LUNG CANCER, 2021, 154 : 176 - 185
  • [4] Safety and Efficacy of First-Line Dacomitinib in Advanced Non-Small Cell Lung Cancer by EGFR Mutation SUBtype in ARCHER 1050
    Pluzanski, A.
    Wu, Y.
    Cheng, Y.
    Zhou, X.
    Migliorino, M. R.
    Niho, S.
    Nakagawa, K.
    Lee, K. H.
    Corral, J.
    Rosell, R.
    Linke, R.
    Tang, Y.
    Pastel, M.
    Wilner, K.
    Mok, T.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S617 - S618
  • [5] Phase III randomized, open label study (ARCHER 1050) of first-line dacomitinib (D) versus gefitinib (G) for advanced (adv) non-small cell lung cancer (NSCLC) in patients (pts) with epidermal growth factor receptor (EGFR) activating mutation(s).
    Mok, Tony
    Nakagawa, Kazuhiko
    Rosell, Rafael
    Wu, Yi Long
    Trygstad, Carl
    Capizzi, Robert L.
    Lee, Min Young
    Tsuji, Fumito
    DeBenedetto, Robert
    Goldberg, Zelanna
    Wang, Tao
    Liang, Jane Q.
    Letrent, Stephen P.
    O'Connell, Joseph P.
    Antic, Vladan
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] First-Line Dacomitinib versus Gefitinib in Advanced Non-Small-Cell Lung Cancer with EGFR Mutation Subgroups
    Wu, Y.
    Cheng, Y.
    Zhou, X.
    Lee, K. H.
    Nakagawa, K.
    Niho, S.
    Tsuji, F.
    Rosell, R.
    Corral, J.
    Migliorino, M. R.
    Pluzanski, A.
    Linke, R.
    Sbar, E.
    Wang, T.
    Zhang, H.
    Mok, T.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1754 - S1754
  • [7] Dacomitinib as first-line treatment for EGFR mutation-positive non-small cell lung cancer
    Reungwetwattana, Thanyanan
    Rohatgi, Nitesh
    Mok, Tony S.
    Prabhash, Kumar
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2021, 6 (03): : 161 - 171
  • [8] Dacomitinib Versus Gefitinib for First-Line Treatment of Advanced EGFR plus NSCLC in Japanese Patients (ARCHER 1050)
    Nakagawa, K.
    Ohyanagi, F.
    Kato, T.
    Takahashi, T.
    Kaneda, H.
    Nogami, N.
    Niho, S.
    Yamamoto, N.
    Fujita, Y.
    Zhang, H.
    Sbar, E.
    Wang, H.
    Linke, R.
    Tsuji, F.
    Mok, T.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2229 - S2230
  • [9] Cost-Effectiveness Analysis of Dacomitinib versus Gefitinib in the First-Line Treatment of EGFR-Positive Advanced or Metastatic Non-Small Cell Lung Cancer
    Zhang, Longfeng
    Li, Na
    Liu, Maobai
    Zheng, Bin
    Wu, Zhijuan
    Cai, Hongfu
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 4263 - 4270
  • [10] ARCHER 1050: first-line dacomitinib vs gefitinib for advanced NSCLC in patients with EGFR activating mutation(s)
    Nakagawa, Kazuhiko
    Mok, Tony S. K.
    Wu, Yi-Long
    Rosell, Rafael
    Tsuji, Fumito
    Wang, Tao
    Sbar, Eric
    ANNALS OF ONCOLOGY, 2015, 26 : 82 - 82
12345